Achalasia
Conditions
Brief summary
Global assessment of chest pain relief after 6 weeks of treatment with citalopram
Detailed description
Symptom frequency and symptom severity score (calculated from symptom diary), Health-related Quality of life (SF-36), Achalasia-specific health-related quality of life (Ach-HRQL), Hospital Anxiety and depression scale (HADS), Adverse events/ complications/ side-effects, Patients estimation about the received treatment (‘’Which treatment did you think you’ve received?’’), Symptom severity and time to perception during esophageal acid perfusion and threshold balloon pressure during esophageal barostat balloon distension test (sub-study).
Interventions
DRUGCitalopram CF 20 mg
DRUGfilmomhulde tabletten
DRUGPlacebo of citalopram 20mg
Sponsors
Amsterdam UMC Stichting
Eligibility
Sex/Gender
All
Age
18 Years to 64 Years
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Global assessment of chest pain relief after 6 weeks of treatment with citalopram | — |
Secondary
| Measure | Time frame |
|---|---|
| Symptom frequency and symptom severity score (calculated from symptom diary), Health-related Quality of life (SF-36), Achalasia-specific health-related quality of life (Ach-HRQL), Hospital Anxiety and depression scale (HADS), Adverse events/ complications/ side-effects, Patients estimation about the received treatment (‘’Which treatment did you think you’ve received?’’), Symptom severity and time to perception during esophageal acid perfusion and threshold balloon pressure during esophageal barostat balloon distension test (sub-study). | — |
Countries
Netherlands
Outcome results
None listed